Autres langues Actinogen Medical Limited

Actions

ACW

AU000000ACW3

Temps Différé Australian S.E. Autres places de cotation 08:10:53 31/05/2024			Varia. 5j.	Varia. 1 janv.
0,029 ^AUD	-.--%		+7,41 %	+31,82 %

15/05	Actinogen Medical ouvre une offre de droits de 3,9 millions de dollars australiens ; les actions sont en baisse de 7%.	MT
03/05	Actinogen Medical lève jusqu'à 8,9 millions de dollars australiens pour l'avancement de l'essai et le fonds de roulement ; les actions chutent de 24%.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	15/05
Rights Issue: 1 new share @ 0.025 AUD for 15 existing shares	09/05	FA
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	03/05
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	22/04
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	15/04
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	15/04
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	25/03
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	07/03
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	25/02
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	15/02
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	28/11
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	13/10/23
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug	27/09/23
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	26/09/23
Actinogen Medical Completes AU$10 Rights Issue	07/09/23
Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23
Rights Issue: 100 new shares @ 0.025 AUD for 454 existing shares	11/08/23	FA
Actinogen Medical to Raise AU$10 Million for Clinical Trial Program; Shares Down 22%	02/08/23
Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention	31/05/23
Actinogen Medical Limited Appoints Nicki Vasquez as a Non-Executive Director	28/02/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Actinogen Medical Limited

Actions

ACW

AU000000ACW3

Autres langues

Filtres